Toronto Innovation Acceleration Partners

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, founded in 2016. The company is focused on developing an innovative injectable hydrogel platform technology designed to enhance drug delivery and improve patient outcomes in various medical applications, particularly in post-surgical pain management, cancer treatment, and other challenging therapeutic areas. AmacaThera's technology features a unique fast-gelling material that liquefies under mechanical force, consisting of a reversible blend of hyaluronan and methylcellulose. This approach allows for localized and sustained drug delivery, potentially reducing postoperative pain and addressing other medical needs effectively.

Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.

Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.

NerveX Neurotechnologies specializes in the development of advanced neuromodulation devices aimed at repairing and enhancing the nervous system. Its flagship product, ANIMO, is an adaptive neural implant that integrates proprietary machine learning and responsive electrical neuromodulation technology. This innovative device is designed to improve sensory functions and assist in the treatment of conditions such as canine epilepsy disorder, providing solutions that can significantly benefit both animals and potentially humans. Through its focus on intelligent neuromodulation, NerveX is positioned at the forefront of neurotechnology, striving to transform the landscape of neurological healthcare.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company focused on treating and preventing cognitive deficits associated with various brain disorders and aging. The company develops small molecule therapeutics aimed at transforming the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Their goal is to enable patients to potentially reverse impairments and resolve previously unresolvable symptoms.

Pearl Interactives specializes in developing interactive media for children of all abilities. Their flagship product, Bootle Blast™, is a mixed reality video game system designed to engage children and youth with neuromotor conditions in exercises that improve functional abilities.

Tabiat operates a software-as-a-service platform that specializes in artificial intelligence-driven remote patient monitoring. The platform is designed to enhance patient outcomes by providing actionable insights that assist healthcare professionals in clinical decision-making. By delivering timely and relevant data, Tabiat enables clinicians to effectively monitor their patients and prioritize care for those in greatest need. This innovative approach not only improves the quality of care but also helps to reduce hospitalizations and associated costs, ultimately allowing healthcare providers to manage more patients efficiently while generating additional revenue.

Founded in 2014, PhenoTips is a Canadian software company specializing in clinical genetics. It offers user-friendly solutions that integrate with existing electronic health records to streamline phenotyping and human phenotype ontology.

Bright Angel Therapeutics develops novel therapeutics targeting stress responses crucial for fungi's survival, virulence, and drug resistance. Its platform aims to enhance current treatment efficacy and eliminate drug resistance, combating life-threatening fungal infections.

Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

Hypercare develops a healthcare coordination platform designed to improve clinical communication and collaboration across departments and specialties. The platform provides secure messaging for clinicians, the ability to share images, videos, and documents, and on-call scheduling to manage shifts and bolster emergency response times. By replacing insecure consumer apps and fragmented paging systems, Hypercare aims to reduce delays, mitigate liability related to patient information, and enhance operational efficiency and patient outcomes for healthcare professionals.

Bright Angel Therapeutics develops novel therapeutics targeting stress responses crucial for fungi's survival, virulence, and drug resistance. Its platform aims to enhance current treatment efficacy and eliminate drug resistance, combating life-threatening fungal infections.

Notch Therapeutics is a Toronto-based company developing immune cell therapies using induced pluripotent stem cell technology to create gene-edited allogeneic T cells. Its platform enables precise control of Notch signaling during T-cell development, enabling scalable manufacture of a uniform supply of therapeutic T cells for cancer indications such as non-Hodgkin lymphoma, leukemia, and multiple myeloma. The approach aims to overcome bottlenecks in cell therapy development by integrating advanced product design with commercially compatible processes, supporting a next-generation pipeline of cell therapies.

Micellae Delivery Systems is a pharmaceutical manufacturing company specializing in advanced drug delivery systems aimed at enhancing the solubility and bioavailability of fat-soluble compounds, particularly cannabinoids. The company provides innovative, intellectual property-protected formulation platforms that enable the development of various dosage forms, including liquids, concentrates, gels, and powders. These formulations cater to a wide range of applications in medical and recreational cannabis, as well as pharmaceuticals, nutraceuticals, and cosmetics. Micellae Delivery Systems focuses on delivering cost-effective, healthy, and sustainable technology to its clients, positioning itself as a leader in the cannabis product market.

Mutuo Health Solutions develops artificial intelligence technology that automatically records and transcribes doctor‑patient interactions. By using any microphone, the system captures dialogue and applies speech recognition and natural language processing to generate suggested clinical notes and electronic medical record actions in real time. This allows medical professionals to concentrate on patient care while the platform handles documentation.

Bitnobi is a software company that specializes in designing and developing data-sharing platforms targeted primarily at the healthcare and finance sectors. The company's innovative platform allows for secure and privacy-protected access to large datasets, eliminating the need for data duplication. By enabling clients to launch data jobs directly and share access to data without creating copies of the original source, Bitnobi streamlines the process of data management and sharing. In addition to its core platform, the company offers services in data, cloud computing, and cybersecurity, aiming to enhance the overall efficiency and security of data handling for its clients.

Nuro Corp, founded in 2017 and based in Waterloo, Canada, specializes in developing neurologically-powered communication software designed to assist doctors and patients. The company offers a range of products under its Neural Operating System (NUOS), which enables instant communication and computing through brain signals, eliminating the need for invasive procedures. Key offerings include NUOS ALS for ALS patients, NUOS TRAUMA for individuals with tetraplegia, and NUOS STROKE for stroke victims. Additionally, NUOS AI provides immediate access to insights derived from neurological and behavioral data, facilitating enhanced communication for incapacitated patients in various healthcare settings, including post-surgery, intensive care units, nursing homes, and rehabilitation facilities.

Zucara Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics to prevent hypoglycemia, or low blood sugar, in patients with diabetes. Established in 2014 and headquartered in Toronto, Canada, with an additional office in Vancouver, Zucara is pioneering a once-daily treatment that aims to regulate the hormone somatostatin in the pancreas. This treatment specifically targets somatostatin type 2 receptors, which are not effectively controlled in patients with Type 1 diabetes. Zucara's approach presents a significant advancement in diabetes care by functioning as a preventative measure against hypoglycemia, contrasting with existing therapies that only provide rescue during acute episodes. Through its pre-clinical technology, Zucara Therapeutics aims to restore natural glucose levels in the blood, ultimately enhancing the quality of life for individuals living with diabetes.

Hypercare develops a healthcare coordination platform designed to improve clinical communication and collaboration across departments and specialties. The platform provides secure messaging for clinicians, the ability to share images, videos, and documents, and on-call scheduling to manage shifts and bolster emergency response times. By replacing insecure consumer apps and fragmented paging systems, Hypercare aims to reduce delays, mitigate liability related to patient information, and enhance operational efficiency and patient outcomes for healthcare professionals.

Purchs is an omnichannel platform that streamlines the sourcing of goods and billing management for merchants. By utilizing conversational commerce and artificial intelligence, the platform allows merchants to scan product UPC codes with their smartphones and complete transactions via text, eliminating the need for logins or traditional checkout processes. For vendors, Purchs provides a comprehensive e-commerce solution tailored for B2B retail sales, enabling them to list products with customized pricing, manage inventory and delivery, handle customer relationships, and automate payment processes—all from a single interface. Additionally, the platform facilitates wholesale distribution and simplifies direct-to-store delivery, helping clients lower their distribution costs and reduce their carbon footprint.